Skip to main content Accessibility help

Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands

  • Tom P. Freeman (a1) (a2), Peggy van der Pol (a3), Wil Kuijpers (a4), Jeroen Wisselink (a4), Ravi K. Das (a2), Sander Rigter (a3), Margriet van Laar (a3), Paul Griffiths (a5), Wendy Swift (a6), Raymond Niesink (a3) and Michael T. Lynskey (a1)...



The number of people entering specialist drug treatment for cannabis problems has increased considerably in recent years. The reasons for this are unclear, but rising cannabis potency could be a contributing factor.


Cannabis potency data were obtained from an ongoing monitoring programme in the Netherlands. We analysed concentrations of δ-9-tetrahydrocannabinol (THC) from the most popular variety of domestic herbal cannabis sold in each retail outlet (2000–2015). Mixed effects linear regression models examined time-dependent associations between THC and first-time cannabis admissions to specialist drug treatment. Candidate time lags were 0–10 years, based on normative European drug treatment data.


THC increased from a mean (95% CI) of 8.62 (7.97–9.27) to 20.38 (19.09–21.67) from 2000 to 2004 and then decreased to 15.31 (14.24–16.38) in 2015. First-time cannabis admissions (per 100 000 inhabitants) rose from 7.08 to 26.36 from 2000 to 2010, and then decreased to 19.82 in 2015. THC was positively associated with treatment entry at lags of 0–9 years, with the strongest association at 5 years, b = 0.370 (0.317–0.424), p < 0.0001. After adjusting for age, sex and non-cannabis drug treatment admissions, these positive associations were attenuated but remained statistically significant at lags of 5–7 years and were again strongest at 5 years, b = 0.082 (0.052–0.111), p < 0.0001.


In this 16-year observational study, we found positive time-dependent associations between changes in cannabis potency and first-time cannabis admissions to drug treatment. These associations are biologically plausible, but their strength after adjustment suggests that other factors are also important.


Corresponding author

Author for correspondence: Tom P. Freeman, E-mail:


Hide All
Behrendt, S, Wittchen, H-U, Höfler, M, Lieb, R and Beesdo, K (2009) Transitions from first substance use to substance use disorders in adolescence: is early onset associated with a rapid escalation? Drug and Alcohol Dependence 99, 6878.
Brunt, TM, van Laar, M, Niesink, RJ and van den Brink, W (2010) The relationship of quality and price of the psychostimulants cocaine and amphetamine with health care outcomes. Drug and Alcohol Dependence 111, 2129.
Cascini, F, Aiello, C and Di Tanna, G (2012) Increasing delta-9-tetrahydrocannabinol (Δ−9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Current Drug Abuse Reviews 5, 3240.
Chan, GC, Hall, W, Freeman, TP, Ferris, J, Kelly, AB and Winstock, A (2017) User characteristics and effect profile of Butane Hash Oil: an extremely high-potency cannabis concentrate. Drug and Alcohol Dependence 178, 3238.
Colizzi, M and Bhattacharyya, S (2017) Does cannabis composition matter? Differential effects of delta-9-tetrahydrocannabinol and cannabidiol on human cognition. Current Addiction Reports 4, 6274.
Courtney, KE, Mejia, MH and Jacobus, J (2017) Longitudinal studies on the etiology of cannabis use disorder: a review. Current Addiction Reports 4, 4352.
Curran, HV, Freeman, TP, Mokrysz, C, Lewis, DA, Morgan, CJ and Parsons, LH (2016) Keep off the grass? Cannabis, cognition and addiction. Nature Reviews Neuroscience 17, 293306.
Di Forti, M, Marconi, A, Carra, E, Fraietta, S, Trotta, A, Bonomo, M et al. (2015) Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The Lancet Psychiatry 2, 233238.
D'Souza, DC, Ranganathan, M, Braley, G, Gueorguieva, R, Zimolo, Z, Cooper, T et al. (2008) Blunted psychotomimetic and amnestic effects of Δ−9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33, 25052516.
ElSohly, MA, Mehmedic, Z, Foster, S, Gon, C, Chandra, S and Church, JC (2016) Changes in cannabis potency over the last 2 decades (1995–2014): analysis of current data in the United States. Biological Psychiatry 79, 613619.
EMCDDA (2014) Report to the EMCDDA by the Reitox National Focal Point. The Netherlands Drug Situation 2014. Luxembourg: Publications Office of the European Union.
EMCDDA (2016) European Drug Report: Trends and Developments. Luxembourg: Publications Office of the European Union.
Englund, A, Freeman, TP, Murray, RM and McGuire, P (2017) Can we make cannabis safer? The Lancet Psychiatry 4, 643648.
Freeman, T and Winstock, A (2015) Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychological Medicine 45, 31813189.
Freeman, TP, Morgan, CJA, Hindocha, C, Schafer, GL, Das, RK and Curran, HV (2014) Just say ‘know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints? Addiction 109, 16861694.
Freeman, TP and Swift, W (2016) Cannabis potency: the need for global monitoring. Addiction 111, 376377.
McLaren, J, Swift, W, Dillon, P and Allsop, S (2008) Cannabis potency and contamination: a review of the literature. Addiction 103, 11001109.
Meier, MH (2017) Associations between butane hash oil use and cannabis-related problems. Drug and Alcohol Dependence 179, 2531.
Mokrysz, C, Freeman, T, Korkki, S, Griffiths, K and Curran, H (2016) Are adolescents more vulnerable to the harmful effects of cannabis than adults? A placebo-controlled study in human males. Translational Psychiatry 6, e961.
Monaghan, M, Hamilton, I, Lloyd, C and Paton, K (2016) Cannabis matters? Treatment responses to increasing cannabis presentations in addiction services in England. Drugs: Education, Prevention and Policy 23, 5461.
Monshouwer, K, Van Laar, M and Vollebergh, WA (2011) Buying cannabis in ‘coffee shops’. Drug and Alcohol Review 30, 148156.
Montanari, L, Guarita, B, Mounteney, J, Zipfel, N and Simon, R (2017) Cannabis use among people entering drug treatment in Europe: a growing phenomenon? European Addiction Research 23, 113.
NDTMS (2014) Adult Drug Statistics from the National Drug Treatment Monitoring System (NDTMS).
Nguyen, H and Reuter, P (2012) How risky is marijuana possession? Considering the role of age, race, and gender. Crime & Delinquency 58, 879910.
Niesink, RJ, Rigter, S, Koeter, MW and Brunt, TM (2015) Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005–15. Addiction 110, 19411950.
Pijlman, F, Rigter, S, Hoek, J, Goldschmidt, H and Niesink, R (2005) Strong increase in total delta-THC in cannabis preparations sold in Dutch coffee shops. Addiction Biology 10, 171180.
Potter, DJ, Clark, P and Brown, MB (2008) Potency of Δ9–THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. Journal of Forensic Sciences 53, 9094.
Schoeler, T, Petros, N, Di Forti, M, Klamerus, E, Foglia, E, Ajnakina, O et al. (2016) Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis: an observational study. The Lancet Psychiatry 3, 947953.
Schubart, CD, Sommer, IE, van Gastel, WA, Goetgebuer, RL, Kahn, RS and Boks, MP (2011) Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research 130, 216221.
Sevigny, EL (2013) Is today's marijuana more potent simply because it's fresher? Drug Testing and Analysis 5, 6267.
Silins, E, Horwood, LJ, Patton, GC, Fergusson, DM, Olsson, CA, Hutchinson, DM et al. (2014) Young adult sequelae of adolescent cannabis use: an integrative analysis. The Lancet Psychiatry 1, 286293.
Smart, R, Caulkins, JP, Kilmer, B, Davenport, S and Midgette, G (2017) Variation in cannabis potency and prices in a newly-legal market: evidence from 30 million cannabis sales in Washington state. Addiction 112, 21672177.
Swift, W, Wong, A, Li, KM, Arnold, JC and McGregor, IS (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS ONE 8, e70052.
UNODC (2016) United Nations Office on Drugs and Crime, World Drug Report 2016 (United Nations publication, Sales No. E.16.XI.7).
van der Pol, P, Liebregts, N, Brunt, T, Amsterdam, J, Graaf, R, Korf, DJ et al. (2014) Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 109, 11011109.
van der Pol, P, Liebregts, N, de Graaf, R, Korf, DJ, van den Brink, W and van Laar, M (2013a) Predicting the transition from frequent cannabis use to cannabis dependence: a three-year prospective study. Drug and Alcohol Dependence 133, 352359.
van der Pol, P, Liebregts, N, Graaf, R, Have, M, Korf, DJ, Brink, W et al. (2013b) Mental health differences between frequent cannabis users with and without dependence and the general population. Addiction 108, 14591469.
Van Laar, M, Van Der Pol, P and Niesink, R (2016) Limitations to the Dutch cannabis toleration policy: assumptions underlying the reclassification of cannabis above 15% THC. International Journal of Drug Policy 34, 5864.
Wisselink, DJ, Kuijpers, WGT and Mol, A (2016) Key Figures Addiction Care 2015. Houten: Stichting Informatie Voorziening Zorg.
Wouters, M and Korf, DJ (2009) Access to licensed cannabis supply and the separation of markets policy in the Netherlands. Journal of Drug Issues 39, 627651.


Related content

Powered by UNSILO
Type Description Title
Supplementary materials

Freeman et al. supplementary material
Figures S1-S7 and Table S1

 PDF (349 KB)
349 KB

Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the Netherlands

  • Tom P. Freeman (a1) (a2), Peggy van der Pol (a3), Wil Kuijpers (a4), Jeroen Wisselink (a4), Ravi K. Das (a2), Sander Rigter (a3), Margriet van Laar (a3), Paul Griffiths (a5), Wendy Swift (a6), Raymond Niesink (a3) and Michael T. Lynskey (a1)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.